TRIP13: A Promising Cancer Immunotherapy Target

Overview

Journal Cancer Innov

Specialty Biomedical Engineering

Date 2024 Oct 14

PMID 39398261

Authors

Shengnan Jing

Liya Zhao

Liwen Zhao

Yong-Jing Gao

Tianzhen He

Affiliations

Soon will be listed here.

Abstract

The tumor microenvironment (TME) facilitates tumor development through intricate intercellular signaling, thereby supporting tumor growth and suppressing the immune response. Thyroid hormone receptor interactor 13 (TRIP13), an AAA+ ATPase, modulates the conformation of client macromolecules, consequently influencing cellular signaling pathways. TRIP13 has been implicated in processes such as proliferation, invasion, migration, and metastasis during tumor progression. Recent studies have revealed that TRIP13 also plays a role in immune response suppression within the TME. Thus, inhibiting these functions of TRIP13 could potentially enhance immune responses and improve the efficacy of immune checkpoint inhibition. This review summarizes the recent research progress of TRIP13 and discusses the potential of targeting TRIP13 to improve immune-based therapies for patients with cancer.

Citing Articles

Therapeutic implications and comprehensive insights into cellular senescence and aging in the tumor microenvironment of sarcoma.

Zan P, Zhang Y, Zhu Y, Chen Q, Duan Z, Guan Y Discov Oncol. 2025; 16(1):50.

PMID: 39812903 PMC: 11735719. DOI: 10.1007/s12672-025-01757-3.

References

Tipton A, Wang K, Oladimeji P, Sufi S, Gu Z, Liu S . Identification of novel mitosis regulators through data mining with human centromere/kinetochore proteins as group queries. BMC Cell Biol. 2012; 13:15. PMC: 3419070. DOI: 10.1186/1471-2121-13-15. View

Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M . The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25(12):677-86. DOI: 10.1016/j.it.2004.09.015. View

Choi J, Gyamfi J, Jang H, Koo J . The role of tumor-associated macrophage in breast cancer biology. Histol Histopathol. 2017; 33(2):133-145. DOI: 10.14670/HH-11-916. View

Lan J, Huang J, Tao X, Gao Y, Zhang L, Huang W . Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways. J Cell Mol Med. 2022; 26(9):2673-2685. PMC: 9077308. DOI: 10.1111/jcmm.17278. View

Lu W, Mengxuan Z, Ming R, Zixu G, Yong Z, Simin Z . TRIP13/FLNA Complex Promotes Tumor Progression and Is Associated with Unfavorable Outcomes in Melanoma. J Oncol. 2022; 2022:1419179. PMC: 9578791. DOI: 10.1155/2022/1419179. View

Xue J, Wu H, Shi Y, Li Z . TRIP13 overexpression in hepatocellular carcinoma: implications for poor prognosis and immune cell infiltration. Discov Oncol. 2023; 14(1):176. PMC: 10516817. DOI: 10.1007/s12672-023-00792-2. View

Ghaffari S, Rezaei N . Eosinophils in the tumor microenvironment: implications for cancer immunotherapy. J Transl Med. 2023; 21(1):551. PMC: 10433623. DOI: 10.1186/s12967-023-04418-7. View

Pollard J . Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4(1):71-8. DOI: 10.1038/nrc1256. View

Jiang D, Liu Y, Wang H, Wang H, Song Q, Sujie A . Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma. Sci Rep. 2017; 7:44823. PMC: 5359661. DOI: 10.1038/srep44823. View

10.

de Palma M, Venneri M, Galli R, Sergi Sergi L, Politi L, Sampaolesi M . Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005; 8(3):211-26. DOI: 10.1016/j.ccr.2005.08.002. View

11.

Sheng N, Yan L, Wu K, You W, Gong J, Hu L . TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer. Cell Death Dis. 2018; 9(3):402. PMC: 5852242. DOI: 10.1038/s41419-018-0434-z. View

12.

Roeder G . Pch2 links chromatin silencing to meiotic checkpoint control. Cell. 1999; 97(3):313-24. DOI: 10.1016/s0092-8674(00)80741-2. View

13.

de Visser K, Korets L, Coussens L . De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005; 7(5):411-23. DOI: 10.1016/j.ccr.2005.04.014. View

14.

Garcia M, Meissburger B, Chan J, de Guia R, Mattijssen F, Roessler S . Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death. Adv Sci (Weinh). 2022; 9(29):e2104291. PMC: 9561781. DOI: 10.1002/advs.202104291. View

15.

Lu C, Liu Y, Ali N, Zhang B, Cui X . The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. Front Immunol. 2023; 13:1039260. PMC: 9893925. DOI: 10.3389/fimmu.2022.1039260. View

16.

Fang Y, Herrick E, Nicholl M . A possible role for perforin and granzyme B in resveratrol-enhanced radiosensitivity of prostate cancer. J Androl. 2011; 33(4):752-60. DOI: 10.2164/jandrol.111.015164. View

17.

Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32(27):2959-66. PMC: 4162494. DOI: 10.1200/JCO.2013.55.0491. View

18.

Angelico G, Broggi G, Tinnirello G, Puzzo L, Vecchio G, Salvatorelli L . Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist's Perspective. Cancers (Basel). 2023; 15(18). PMC: 10526828. DOI: 10.3390/cancers15184479. View

19.

Sica A, Bronte V . Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007; 117(5):1155-66. PMC: 1857267. DOI: 10.1172/JCI31422. View

20.

Kreike B, Van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H . Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9(5):R65. PMC: 2242660. DOI: 10.1186/bcr1771. View